Seattle BioMed researchers today announced they have developed a next generation genetically attenuated parasite (GAP) that might constitute the path to a highly protective malaria vaccine. The study was published online in the journal Molecular Therapy.
Jason Beaubien, global health and development correspondent of National Public Radio (NPR), will deliver the keynote address at the Passport to Global Health Celebration on March 5.
Seattle BioMed researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine. The study was published online in PLOS One.
Seattle BioMed’s BioQuest Program Receives $10,000 Grant From Yakima Valley Community Foundation to Expand Existing Partnership with Two Local High Schools
Researchers at Seattle BioMed are using systems biology to discover how liver cells infected with malaria parasites are more vulnerable than previously thought, and that existing drugs can be leveraged to force those infected cells to self destruct while leaving the healthy cells intact.
Seattle BioMed has been awarded a grant that will take a comprehensive systems approach to the problem of tuberculosis (TB) infection, harnessing the power of technology and systems biology to examine the progression from latent infection to disease.
The influenza virus’ ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection. The results are published this month in the journal Cell.
Researchers have taken the first steps toward a complete representation of the regulatory network for Mycobacterium tuberculosis. This map will yield unique insights into how the bacteria survive in the host.
Discovery of how parasite sticks to blood vessels could lead to new means to combat malaria.
For the first time, researchers were able to stimulate immune cells to produce broadly neutralizing antibodies: a critical step that has eluded researchers for decades but that provides promise for a successful HIV vaccine.
Scientists tested the efficacy of cancer drugs at killing the malaria parasite during the liver phase with astonishing success. This research paves the way for future studies using cancer drugs that could cause less drug resistance and have more targeted treatments than conventional malaria drugs.
The Seattle Structural Genomics Center for Infectious Disease and the Center for Structural Genomics of Infectious Diseases announced today they will receive up to $52.4 million over five years, from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators at the Center for Structural Genomics of Infectious Diseases (CSGID) and the Seattle Structural Genomics Center for Infectious Disease (SSGCID) announced today that they reached a significant milestone by determining 1,000 protein structures from infectious disease organisms. The knowledge gained from these structures should lead to new interventions for the deadly diseases caused by these pathogens.
Researchers from Seattle BioMed, University of Copenhagen and University of Edinburgh have uncovered new knowledge related to host-parasite interaction in severe malaria, concerning how malaria parasites are able to bind to cells in the brain and cause cerebral malaria – the most lethal form of the disease. “Identifying the molecules that allow malaria parasites to ‘stick’ to the brain takes us one step closer to new treatments,” said Joseph Smith, Ph.D., leader of the Seattle team.
Discovery helps researchers advance future TB vaccine design.
Special journal edition chronicles 3D structures of Important antibacterial and bioterrorist targets.
Seattle BioMed’s Aderem shares Insight into rational vaccine development using new approaches.
Useful for identifying immunologic factors that lead to AIDS in HIV-infected patients.
Scientists at Seattle Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the planet. As leaders of two large structural genomics centers, they’ve experimentally determined 500 three-dimensional protein structures from a number of bacterial and protozoan pathogens, which could potentially lead to new drugs, vaccines and diagnostics to combat deadly infectious diseases.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right